Objective-Reasons for variations in atherosclerotic burden among individuals with similar levels of obesity are poorly understood, especially in African Americans. This study examines whether high-sensitivity C-reactive protein (hsCRP) is useful for discriminating between benign and high-risk obesity phenotypes for subclinical atherosclerosis in African Americans. Approach and Results-Participants from the Jackson Heart Study (n=4682) were stratified into 4 phenotypes based on the presence of National Heart and Lung and Blood Institute definition of obesity or obesity-equivalent (body mass index ≥30 or body mass index 25-30 with waist circumference >102 cm in men and >88 cm in women) and inflammation by hsCRP ≥2 mg/L. Using multivariate regression models, we conducted cross-sectional analyses of the association between inflammatory obesity phenotypes and subclinical atherosclerosis determined by carotid intima-media thickness or coronary artery calcium scores. Sex-specific analyses were conducted given significant interaction for gender (P=0.03). The prevalence of obesity or equivalent was 65%, of which 30% did not have inflammation. Conversely, 37% of nonobese individuals had inflammation. Among nonobese men, hsCRP ≥2 mg/L identified a subset of individuals with higher carotid intima-media thickness (adjusted mean difference =0.05, 95% confidence interval 0.02, 0.08 mm) compared with their noninflammatory counterparts. Among obese men, hsCRP <2 mg/L identified a subset of individuals with lower coronary artery calcium compared with their inflammatory counterparts. Among women, associations between hsCRP and carotid intima-media thickness or coronary artery calcium were not found. 
A mong African American (AA) adults, 76% are overweight or obese and 19% have diabetes mellitus, rates that are substantially higher than in the general population (66% and 11%, respectively). [1] [2] [3] Both excess obesity and diabetes mellitus are major risk factors for cardiovascular disease, 1,3 determinants of which, if better understood, may translate into more successful prevention efforts to mitigate disparities in the prevalence of diabetes mellitus and cardiovascular disease in AAs. 4 Data from mostly White cohorts suggest that the presence of inflammation is one factor that could be helpful in discriminating between the benign and high-risk phenotypes across body mass index (BMI) and waist circumference-based classifications of obesity. [5] [6] [7] [8] High-sensitivity C-reactive protein (hsCRP)
is an easy-to-measure and inexpensive inflammatory biomarker that has been associated with obesity and atherosclerotic disease burden. 5 Therefore, it is possible that inflammation, or its absence as measured by hsCRP, could be helpful in explaining the variation in the subclinical atherosclerosis, if any, associated with obesity among AAs by identifying a subset of obese individuals without an increased atherosclerotic burden (benign obesity) compared with nonobese individuals. It may also help to identify, if it exists, a nonobese subpopulation that has a higher burden of subclinical atherosclerosis compared with their noninflammatory counterparts. This is especially important because median hsCRP levels are known to be higher in AAs than in whites; therefore, hsCRP in AAs have the potential Because there is a paucity of information that characterizes the interaction between obesity and inflammation as they relate to subclinical atherosclerosis in the AA population, we studied whether the inflammatory obesity phenotype was related to subclinical carotid or coronary atherosclerosis, as measured by carotid intima-media thickness (cIMT) and coronary artery calcium (CAC) scores, respectively. We performed this analysis using the largest population-based observational cohort of AAs to date, the Jackson Heart Study (JHS). We hypothesize that hsCRP levels will identify a subset of nonobese AA adults with a higher atherosclerotic burden related to inflammation and another subset of obese AA adults without inflammation with a lower burden of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Participants from the Jackson Heart Study (n=4682) were stratified into 4 phenotypes based on the presence of NHLBI definition of obesity or obesity-equivalent (BMI ≥30 or BMI 25-30 with waist circumference >102 cm in men and >88 cm in women) and inflammation by hsCRP ≥2 mg/L. Alternatively, we conducted sensitivity analyses using a cut-point of the upper quartile of gender-obesityspecific hsCRP levels to define inflammation. Using multivariate regression models, we conducted cross-sectional analyses of the association between inflammatory obesity phenotypes and subclinical atherosclerosis determined by carotid intima-media thickness (cIMT) or coronary artery calcium scores (CAC).
Results

Baseline Characteristics
Of 4682 individuals without cerebrovascular disease at baseline, 65% of them met study criteria for obesity based on BMI and waist circumference. We found 37% of nonobese individuals with significant inflammation by hsCRP ≥2 mg/L criteria, while 30% of obese participants did not have significant mm Hg, DBP ≥90 mm Hg, and use of blood pressure-lowering medications in 2 wk before baseline visit; Hypercholesterolemia, fasting total cholesterol ≥240 mg/dL, fasting LDL cholesterol ≥160 mg/dL, and use of cholesterol-lowering medications in 2 wk before baseline visit; Coronary artery disease: history of physician-diagnosed myocardial infarction, coronary revascularization procedure, or abnormal stress test; Peripheral vascular disease: peripheral vascular surgery, angiography, or revascularization; Diabetes mellitus: Fasting glucose ≥126 mg/dL, hbA1c ≥6.5%, and use of antidiabetic medications in 2 wk before baseline visit. ANOVA indicates analysis of variance; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; and NHLBI, National Heart and Lung and Blood Institute.
*Obesity defined based on NHLBI recommendations, using a combination of BMI and gender-specific waist circumference thresholds.
inflammation. The baseline characteristics of the overall and the 4 inflammatory obesity phenotypes (groups 1 through 4) of AA individuals are summarized in Table 1 . Compared with the other 3 groups of participants with either obesity, inflammation, or both, individuals from group 1 were more likely to be younger, male, and less likely to have a history of hypertension. Among the nonobese individuals, those with hsCRP ≥2 mg/L (group 2) were more likely to be current smokers. Compared with group 1, obese individuals, with or without inflammation, tended to have a higher prevalence of diabetes mellitus and hypercholesterolemia, but have a lower prevalence of alcohol use.
BMI and hsCRP
BMI and hsCRP values were significantly correlated in the overall population (both men and women; Table 2 ). Figure 1 showed hsCRP levels to be similar between men and women across inflammatory obesity phenotypes except for group 4 (obese and inflammatory), where women have higher hsCRP levels (mean hsCRP for women =8.77 and for men =6.67 mg/L; P<0.01). In contrast, men had greater average waist circumference and BMI values compared with women, with the exception of group 4, where women had a significantly higher BMI (P<0.05; in Figures III and IV in the online-only Data Supplement). Table 2 showed hsCRP levels to be significantly correlated with cIMT in men but not in women, and they were not correlated with CAC. BMI was found to be significantly correlated with CAC in men but not in women, and it was not correlated with cIMT.
Obesity Phenotypes and cIMT
Women had lower mean cIMT values than men across all obesity phenotypes (P value <0.05 for all comparisons), with the exception of group 3 (P=0.30; Figure 2 ). In addition, mean cIMT values were significantly different across inflammatory obesity phenotypes (P<0.01), with the lowest cIMT values found in individuals of group 1. Adjusted analyses in Table 3 showed obese men and women, irrespective of hsCRP levels (groups 3 and 4), to have significantly higher cIMT values compared with group 1 (referent). However, the association between inflammatory obesity phenotypes and cIMT differed by gender (P=0.03 for interaction). Elevated hsCRP values identified a subgroup of nonobese men (group 2), but not women, with higher cIMT values compared with group 1. Further adjustment by BMI and waist circumference did not significantly change these results. This relationship was maintained for low-risk individuals, such as those without prior coronary artery or peripheral vascular disease. Use of alternative hsCRP thresholds to define inflammation derived from gender-and obesity-specific cut points (baseline characteristics of the obesity phenotypes reclassified are shown in Table I in the online-only Data Supplement) did not qualitatively change the results (Table II in Table III in the online-only Data Supplement. Between visits 1 and 2, significant increases in BMI and waist circumference occurred for both men and women, whereas only men had significant increases in hsCRP levels. The baseline characteristics of this subsample (Table  IV in the online-only Data Supplement) were similar to those of the overall population described for Table 1 . Of these individuals, 42% had coronary atherosclerosis (CAC>0). Similar to cIMT results, women had a lower prevalence of coronary atherosclerosis (38.3% for women versus 47.8% for men; P<0.01) and lower mean CAC scores (81.17, 95% confidence interval 68.44, 93.90 in women versus 156.12, 95% confidence interval 122.12, 190.13 in men; P<0.01) than men. In men, mean CAC scores were significantly different across the 4 inflammatory obesity phenotypes (P<0.01), whereas mean CAC scores were similar among the 4 obesity phenotypes in women (P=0.23; Figure 3 ).
Gender-specific adjusted analyses in Table 4 showed that elevated hsCRP values identified a subgroup of obese AA men, but not women, with an increased prevalence of coronary atherosclerosis (prevalence odds ratio for binary CAC =1.36, 95% confidence interval 1.14, 1.63; prevalence odds ratio for multicategorical CAC =1.79, 95% confidence interval 1.20, 2.66). In contrast to cIMT findings, hsCRP did not identify a higher risk phenotype among the nonobese groups (group 1 versus 2). No significant difference was noted after additional adjustment for BMI change, hsCRP change, and change in waist circumference that occurred between visits 1 and 2. When using gender-and obesity-specific quartiles of hsCRP to restratify the obesity phenotypes, results were not qualitatively different, except that the associations were slightly enhanced in the multicategorical CAC analyses for men (Table V in the online-only Data Supplement).
Discussion
In the largest AA population-based cohort to date, free of cerebrovascular disease at baseline, we found that 30% of obese participants did not have an hsCRP ≥2 mg/L, whereas 37% of nonobese individuals had an hsCRP ≥2 mg/L. For women, hsCRP did not discriminate the burden of either carotid or coronary atherosclerosis. In contrast, among men, hsCRP ≥2 mg/L identified a subset of nonobese individuals with higher burden of carotid atherosclerosis. In presence of obesity, hsCRP <2 mg/L identified a subset of men with lower burden of coronary atherosclerosis. Despite this last finding, benign obesity did not exist because all phenotypes of obesity were associated with higher carotid atherosclerotic burden in both men and women irrespective of inflammation. Thus, hsCRP utility seems to primarily identify a subgroup of nonobese men with higher burden of carotid atherosclerosis.
Although previous studies have shown men to have higher cIMT than women, 10, 11 to our knowledge, this is the first study that shows gender differences in the association between inflammation and atherosclerosis, where hsCRP ≥2 mg/L was related to higher cIMT in nonobese men but not in women. Results from Multiethnic Study of Atherosclerosis (MESA; 28% AA) 12 and Dallas Heart cohort (47% AA) 13 
Figure 2.
Mean carotid intima-media thickness (cIMT) and 95% confidence intervals (CI) across inflammatory obesity phenotypes by gender. Women had lower mean cIMT values than men across all obesity phenotypes with the exception of group 3 (P value <0.05 for all comparisons except P=0.30 for group 3). In men and women, mean cIMT differed significantly across the 4 inflammatory obesity phenotypes, with the lowest mean cIMT values in the nonobese, noninflammatory group (P<0.001 for men and women). hs-CRP indicates highsensitivity C-reactive protein. demonstrated that a high hsCRP value was useful in identifying an at-risk group of nonobese individuals with higher prevalence of subclinical atherosclerosis but the authors did not find a significant gender effect on the outcomes. However, in an analysis of 52 prospective studies (n=246 669) to predict cardiovascular events, the investigators found a significant gender heterogeneity in the association between hsCRP and future cardiovascular events, where the association was stronger in men than in women. 14 The reason for such gender disparity in the association between obesity, inflammation, and atherosclerosis is unknown, particularly in AAs. It is possible that the lack of association between hsCRP and atherosclerosis in women relates to physiologically higher hsCRP levels found in women, unrelated to inflammation. 15 It has been postulated that a portion of hsCRP production is related to peripheral estrogen levels, which may affect liver production of hsCRP, thus, independent of systemic inflammation and other inflammatory markers, such as interleukin-6. 16, 17 These studies have shown that these estrogen-induced changes in hsCRP are not associated with angiographic progression of atherosclerosis 17, 18 and may explain the lack of utility hsCRP to identify women with higher atherosclerosis burden in our study. However, the overall lower prevalence of either significant carotid or coronary atherosclerosis in AA women across all obesity phenotypes compared with men (Tables 3 and 4) may also have reduced our power to detect small differences in atherosclerosis within obesity phenotypes for women. This lower prevalence of atherosclerosis in women is not unique to the JHS cohort and has also been shown in Dallas Heart Study and MESA cohorts. 17, 18 Although we initially used hsCRP ≥2 mg/L to define inflammation, it is also possible that distinct thresholds for Regression model adjusted for age, smoking history, alcohol use, peripheral vascular disease or coronary artery disease, hypertension, hypercholesterolemia, and diabetes mellitus. cIMT indicates carotid intima-media thickness; hs-CRP, high sensitivity C-reactive protein; and NS, non-significant.
*Subgroup analysis comparing hs-CRP <2 mg/L and hs-CRP ≥2 mg/L among the obese; P value significant at P<0.025. BMI and hsCRP are needed to define a relationship between obesity phenotypes and atherosclerosis in AA women. In our study, gender-and obesity-specific thresholds (upper quartile) for hsCRP were much higher in obese women (hsCRP ≥7.83 mg/L) than in obese men (hsCRP ≥4.68 mg/L). When genderand BMI-specific tertiles of hsCRP were used in the Dallas Heart cohort, an association between hsCRP and coronary atherosclerosis was found among obese women, but with a cutoff for hsCRP set at >9.9 mg/L. 13 However, gender-and BMIspecific thresholds for hsCRP in our study did not significantly change our results. The discrepant findings between our cohort and the Dallas Heart cohort may be related to racial differences in the BMI/waist circumference-based cutoffs for obesity and that different level of hsCRP are elicited in response to the same anthropometric definition of obesity. For example, an hsCRP cutoff of 9.9 mg/L used in Dallas Heart Study would correspond to the 86th percentile of the women in our JHS cohort. Given that studies have shown that ethnicity modifies mean hsCRP levels in women 19 and additional differences in the estrogen profile may exist across ethnicities, 20 future studies are needed to further elucidate the adequate hsCRP cutoffs, if it exists, for identifying atherosclerosis in obese AA women.
It is also possible that hsCRP may not be the best inflammatory marker for women. In the Nurses' Health Study and the Health Professionals Follow-up Study, elevated plasma levels of soluble tumor necrosis factor-α receptors (sTNF-R1 and sTNF-R2) were related to an increased risk of future coronary heart disease among women, but not men. 21 However, these associations were no longer significant after adjustment for BMI, diabetes mellitus, and hypertension. The only biomarker that remained significant was hsCRP for both men and women. Fibrinogen is an alternative inflammatory biomarker that could be considered for phenotypic recognition in AA women. Although fibrinogen also seems to have gender differences similar to hsCRP, 14 it seems to have a higher concentration among AA women 22 and was significantly associated with cIMT among AA women. 23 Interleukin-6 is another inflammatory marker associated with CAC and significant coronary stenosis in AA adults. 24 Compared with hsCRP, interleukin-6 has a stronger association with both cIMT and CAC 24, 25 and subclinical cerebrovascular disease. 26 However, there was no evidence of gender-specific effects of interleukin-6 and atherosclerosis.
Our study failed to show the existence of a benign obesity phenotype because obesity was associated with higher cIMT Overall P value ‡ 0.07
Models adjusted for age, smoking history, alcohol use, hypertension, hypercholesterolemia, cerebrovascular disease/stroke, peripheral vascular disease, and diabetes mellitus. CAC indicates coronary artery calcium; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; NS, non-significant; and POR, prevalence odds ratios.
*Ordinal CAC: categorized as CAC = 0; CAC = 1-10; CAC = 11-100; CAC= 101-300; CAC >300. †Binary CAC: categorized as CAC>0 vs CAC=0. ‡Compared using transformed values of log (CAC +1). §Subgroup analysis comparing hs-CRP <2 mg/L and hs-CRP ≥2 mg/L among the obese; P value significant at P<0.025.
in both men and women irrespective of hsCRP levels. Similar results were found in MESA where obesity was associated with coronary atherosclerosis in both men and women with and without elevated hsCRP. 12 We also noticed that the association between risk factor (in our case obesity and hsCRP) and atherosclerosis appeared to vary by vascular territory, a phenomenon well described in the past. Examples of such was in the Framingham Heart Study, which demonstrated that the excess risk attributed to hypertension is higher for stroke (3.8× in men and 2.6× in women) than for coronary disease (≈2 times for men and women), 27 an excess risk that also varied by gender. Moreover, in 1632 participants from MESA, HOMA-IR (the Homeostatic Model Assessment of Insulin Resistance) was associated with the presence of CAC, but not abdominal or thoracic aortic calcium, 28 further supporting distinct mechanisms that may lead to atherosclerosis in different vascular territories. It is theorized that different vascular territories with different luminal diameters have distinct hemodynamic stresses that may predispose them to unique mechanisms of atherosclerosis, [29] [30] [31] mechanisms and risk factors that vary by gender and ethnicity. [32] [33] [34] When the effect of inflammation was studied as a risk factor, it has been demonstrated to be dependent on vascular territory, gender, and race. 13, 31 Example of such distinct correspondence between risk factor and vascular territory was also present in the men portion of our study cohort, where hsCRP but not BMI was significantly correlated to cIMT, whereas BMI but not hsCRP was significantly correlated to CAC ( Table 2) .
The study has several limitations. The study is observational, and the analyses are cross-sectional; therefore, we cannot determine temporality or causality of the relationships found. Although we noticed a similar trend in identifying nonobese men at risk for subclinical disease in both cIMT and CAC, it was not significant for CAC. This may be related to a reduction in power given the attrition between visit 1 and visit 2. It is also possible that our exclusion of individuals with symptomatic vascular disease has selected out the highest risk population for atherosclerosis and, therefore, underestimated the relationship between inflammatory obesity and atherosclerosis. But, this type of design is useful to determine the additive value of biomarker phenotyping in the risk stratification of seemingly asymptomatic patients who could be at risk for future cardiovascular events related to the increased atherosclerosis burden. Although we used the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) cutoff of hsCRP ≥2 mg/L to discriminate between high and low inflammation burden, we also used gender-and obesityspecific cutoffs as sensitivity analyses given recent studies that have found higher hsCRP cutoffs may provide higher specificity in the women and the obese. 13, 35 Although these radiographic markers of atherosclerosis are correlated with traditional CV risk factors 36, 37 and incident CVD, 38-41 they cannot directly be extrapolated to cardiovascular outcomes. Further longitudinal analysis will be needed to clarify the association between hsCRP, in conjunction with other biomarkers, to cardiovascular events across gender-specific obesity phenotypes in AAs.
In conclusion, in the largest AA population-based cohort to date, hsCRP ≥2 mg/L was useful in identifying a subset of nonobese men with higher cIMT, but not in women. hsCRP <2 mg/L did not identify a subset of obese AAs with less subclinical atherosclerosis. This would suggest alternative hsCRP cutoffs or other biomarkers more suitable to the female AA population that remain unexplored.
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